Cellebrite DI vs Strategy
Strategy reported revenue of $477 million in fiscal 2025, about the same as Cellebrite DI's $476 million in fiscal 2025. Cellebrite DI's revenue grew 18.6% in its latest year, and Strategy's grew 3.0%. Cellebrite DI had an operating margin of 14.0%, against -1140.8% at Strategy. Free cash flow was $160 million at Cellebrite DI and −$75 million at Strategy.
Side by side
| Cellebrite DI | Strategy | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $476M | $477M |
| Revenue growth | 18.6% | 3.0% |
| Revenue growth a year, last 5 years | 19.5% | −0.1% |
| Gross margin | 84.2% | 68.7% |
| Operating margin | 14.0% | −1,140.8% |
| Net margin | 16.5% | −806.4% |
| Free cash flow | $160M | −$75M |
| Free cash flow margin | 33.7% | −15.8% |
| Return on capital | — | −11.4% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 19.3% | 44.2% |
| Last close | $11.32 | $86.13 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $5.5 million | bought $2.2 million, sold $30.5 million |
| Piotroski F-score | — | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cellebrite DIStrategy
Operating margin
Percent of revenue
Cellebrite DIStrategy
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cellebrite DIStrategy
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cellebrite DI and Strategy pages.